Will minoxidil work for me?

If you have started looking into treatment for hair loss, you have almost certainly come across Minoxidil. It is the most widely used topical hair-loss treatment in the UK, available as both a 2 per cent and 5 per cent solution or foam, and it is licensed for androgenetic alopecia — the pattern hair loss that affects a large proportion of men and women across adulthood. The question patients ask most often is the most honest one: will it actually work for me?

There is no way to answer that question for any single person before they try. What clinicians can do is set out who tends to respond, why response varies, what to look for in the first six months, and what realistic next steps look like if the result is partial or absent. This article is a walk through all of that.

How minoxidil works and who it tends to help

Minoxidil is a vasodilator that was originally developed as a blood pressure medication. Its effect on hair was an unexpected finding, and the topical formulation now used for hair loss works locally on the scalp rather than systemically in any meaningful way. Its main action is on the hair cycle: it prolongs the anagen, or growth, phase of follicles that are still active, and it shifts some resting follicles back into growth. The visible effect for the right patient is thicker, longer hair shafts in the areas that have started to thin.

The patients minoxidil tends to help most are those with relatively recent, early-stage pattern hair loss — a receding hairline that has changed over the last one to three years, or diffuse thinning at the crown that has not yet progressed to bare scalp. Where follicles still exist but are producing finer, shorter hairs, minoxidil has something to work with. Where follicles have miniaturised so far that the area is genuinely bald, the medicine has very little to do. This is one of the most consistent patterns in the published evidence: response correlates with how much active follicle is still on the scalp at the start.

It is licensed in the UK for androgenetic alopecia in both men and women, and the BNF entry for minoxidil sets out the licensed indications and cautions. Other forms of hair loss — alopecia areata, scarring alopecias, hair shedding secondary to illness or thyroid disease — have a different mechanism and are managed differently. Speaking to a clinician first is what gives you a useful baseline answer to whether minoxidil is even the right tool.

Why response varies between people

Two patients with very similar-looking hair loss can use minoxidil the same way for the same length of time and have very different outcomes. There are a few reliable reasons for that.

The first is the stage of follicle miniaturisation. Minoxidil acts on follicles that are still cycling — even if they are producing very fine hairs. Follicles that have stopped cycling do not restart on a topical alone, regardless of how diligent the patient is.

The second is consistency. The medicine has to be applied daily, to dry scalp, and left on. The studies that produced the 40 to 60 per cent response figure were done with patients who used it as directed for six to twelve months. Inconsistent use — skipping days, washing off after a short interval, applying to only the most visible patch — typically produces a smaller benefit than the published data suggest.

The third is the rest of the picture: age, family history, how long the loss has been progressing, whether anything else is contributing (iron deficiency, thyroid disturbance, telogen effluvium from illness or stress, certain medications). A clinician will usually ask about all of this before recommending treatment, partly to make sure something reversible is not being missed.

Finally, there is biology that science has not fully explained. Some people simply convert minoxidil into its active form less efficiently in the scalp than others, and that appears to influence response. This is a known reason for non-response and is not anything a patient has done wrong.

Signs minoxidil is starting to work

The most common surprise for patients in the first weeks of minoxidil is shedding. A noticeable increase in hairs in the shower, on the pillow, or in a brush during weeks two to eight is well-recognised and almost always temporary. What is happening biologically is that resting follicles are being pushed into a new growth cycle, and to do that the old, thin hair has to be released first. Most people who go on to respond well to minoxidil go through some version of this shedding phase. It is not failure, and it is not a reason to stop without a conversation.

Between months three and six, the signs of a genuine response — when one is happening — usually include:

• Slightly thicker hair shafts in the treated area, often most visible at the parting or crown.
• Less scalp showing through under bathroom lighting.
• A finer fringe of new hairs along the hairline or temples, sometimes lighter in colour at first.
• Less overall daily shedding compared to the baseline before treatment.

By six months of consistent use, most UK clinicians review with the patient whether the picture has improved, stayed stable, or continued to decline. Six months is the agreed point because the hair cycle is slow — earlier than that is too soon to judge fairly. Standardised photos taken at the start and at six months under similar lighting are often more useful than trying to remember.

When to stop and what to try next

If, after six months of daily application, there has been no visible benefit and no slowing of the loss, that is the conversation to have with your clinician about next steps. Continuing minoxidil indefinitely in a true non-responder is unlikely to deliver something it has not delivered in half a year.

Several routes can be considered at that point. One is a change of strength or formulation — for example, moving between solution and foam where tolerability is the issue, or revisiting frequency. Another is a clinician review to look for contributors that may have been overlooked, including iron studies, thyroid function and a review of other medications.

For androgenetic alopecia specifically, adding a second-mechanism medication can be the right step. Finasteride works on the hormonal driver of male pattern hair loss by reducing scalp DHT, while minoxidil works on the follicle cycle. The two together address the problem from two different angles, and in some patients a partial responder to one becomes a clearer responder when both are used. Whether finasteride is appropriate depends on individual factors and is a clinician-led decision — our piece on how much finasteride to take for hair loss sets out what UK prescribers usually consider. There are also other contributors to consider; for some patients, related questions like whether low testosterone causes hair loss come up at the same review.

Stopping minoxidil after a period of benefit is its own decision. Because the medicine acts only while it is on the scalp, follicles return to their previous behaviour over the following three to six months, and gains will typically be lost. For patients who have responded well, that means treatment is generally a long-term commitment rather than a course.

Combining minoxidil with finasteride

Combination therapy is a recognised approach in UK clinical practice and is set out in the broader NICE-equivalent dermatology framework for androgenetic alopecia. Minoxidil tackles the follicle cycle directly; finasteride reduces the systemic hormonal pressure that is driving miniaturisation. Because the two act independently, they can be additive rather than competing, and combination has good evidence for slowing further loss and increasing the proportion of patients who see regrowth.

The combination is not suitable for every patient. Finasteride has its own list of considerations — it is not used in women of childbearing potential, side effects are uncommon but recognised, and it is a longer-term decision rather than a casual addition. A clinician will assess the pattern of loss, age, general health and personal preference before recommending it.

For women with female pattern hair loss, topical minoxidil remains the licensed first-line option in the UK, usually at the 2 per cent strength, although 5 per cent is sometimes used off-licence by clinicians. The combination route for women is different and individualised.

Setting realistic expectations

The most important thing to take away is this: minoxidil is a long-game medicine. It will not give an overnight transformation, it will not regrow hair on bare scalp, and it works gradually. For roughly half of patients with suitable hair loss, it can slow progression and produce visible regrowth — modest in some, more noticeable in others. For the other half, the result is partial or absent, and that is part of the realistic picture, not a reflection on how hard the patient tried.

What patients tend to find most useful is a clear plan at the start: a baseline photo, a clear six-month review point, an honest conversation about what counts as success, and a clinician they can speak to if they are uncertain whether to continue. Whether the answer at six months is "carry on", "add finasteride", or "change route", it is a more constructive conversation when there is a baseline to compare against.